Literature DB >> 12873656

Prospective study of fibrinolytic markers and venous thromboembolism.

Aaron R Folsom1, Mary Cushman, Susan R Heckbert, Wayne D Rosamond, Nena Aleksic.   

Abstract

Prior research has conflicted on whether increased levels of plasma fibrinolytic factors may identify patients at risk of venous thromboembolism (VTE). We therefore performed a nested case-control study of VTE within two prospective population-based studies. In 308 participants who developed VTE and 640 controls, we measured PAI-1 antigen, tPA/PAI-1 complex, plasmin-alpha 2-antiplasmin (PAP), and the PAI-1 -675 4G/5G promoter polymorphism on pre-event blood samples. There was no overall association between any of these fibrinolytic variables and VTE, after adjustment for age or for multiple VTE risk factors. There was weak evidence for an interaction of PAP with elevated factor VIIIc and elevated D-dimer in augmenting VTE risk. We conclude that, for the most part, these fibrinolytic markers do not identify healthy subjects at risk for VTE.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12873656     DOI: 10.1016/s0895-4356(03)00052-0

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  22 in total

Review 1.  Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms.

Authors:  Keattiyoat Wattanakit; Mary Cushman
Journal:  Curr Opin Pulm Med       Date:  2009-09       Impact factor: 3.155

2.  Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology.

Authors:  Mary Cushman; Ellen S O'Meara; Susan R Heckbert; Neil A Zakai; Wayne Rosamond; Aaron R Folsom
Journal:  Thromb Res       Date:  2016-06-15       Impact factor: 3.944

Review 3.  Epidemiology of venous thromboembolism.

Authors:  John A Heit
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

4.  Mechanisms and mitigating factors for venous thromboembolism in chronic kidney disease: the REGARDS study.

Authors:  K L Cheung; N A Zakai; P W Callas; G Howard; B K Mahmoodi; C A Peralta; S E Judd; M Kurella Tamura; M Cushman
Journal:  J Thromb Haemost       Date:  2018-08-09       Impact factor: 5.824

Review 5.  Fibrinolysis and the control of blood coagulation.

Authors:  John C Chapin; Katherine A Hajjar
Journal:  Blood Rev       Date:  2014-09-16       Impact factor: 8.250

6.  Metabolic syndrome and risk of venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology.

Authors:  L M Steffen; M Cushman; J M Peacock; S R Heckbert; D R Jacobs; W D Rosamond; A R Folsom
Journal:  J Thromb Haemost       Date:  2009-01-19       Impact factor: 5.824

7.  Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis?

Authors:  Valeria Rossetto; Luca Spiezia; Marco Senzolo; Krissia Isabel Rodriguez-Castro; Sabrina Gavasso; Barry Woodhams; Paolo Simioni
Journal:  Intern Emerg Med       Date:  2013-03-17       Impact factor: 3.397

Review 8.  The epidemiology of venous thromboembolism in the community: implications for prevention and management.

Authors:  John A Heit
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

9.  Genome-wide association study for circulating tissue plasminogen activator levels and functional follow-up implicates endothelial STXBP5 and STX2.

Authors:  Jie Huang; Jennifer E Huffman; Munekazu Yamakuchi; Munekazu Yamkauchi; Stella Trompet; Folkert W Asselbergs; Maria Sabater-Lleal; David-Alexandre Trégouët; Wei-Min Chen; Nicholas L Smith; Marcus E Kleber; So-Youn Shin; Diane M Becker; Weihong Tang; Abbas Dehghan; Andrew D Johnson; Vinh Truong; Lasse Folkersen; Qiong Yang; Tiphaine Oudot-Mellkah; Brendan M Buckley; Jason H Moore; Frances M K Williams; Harry Campbell; Günther Silbernagel; Veronique Vitart; Igor Rudan; Geoffrey H Tofler; Gerjan J Navis; Anita Destefano; Alan F Wright; Ming-Huei Chen; Anton J M de Craen; Bradford B Worrall; Alicja R Rudnicka; Ann Rumley; Ebony B Bookman; Bruce M Psaty; Fang Chen; Keith L Keene; Oscar H Franco; Bernhard O Böhm; Andre G Uitterlinden; Angela M Carter; J Wouter Jukema; Naveed Sattar; Joshua C Bis; Mohammad A Ikram; Michèle M Sale; Barbara McKnight; Myriam Fornage; Ian Ford; Kent Taylor; P Eline Slagboom; Wendy L McArdle; Fang-Chi Hsu; Anders Franco-Cereceda; Alison H Goodall; Lisa R Yanek; Karen L Furie; Mary Cushman; Albert Hofman; Jacqueline C M Witteman; Aaron R Folsom; Saonli Basu; Nena Matijevic; Wiek H van Gilst; James F Wilson; Rudi G J Westendorp; Sekar Kathiresan; Muredach P Reilly; Russell P Tracy; Ozren Polasek; Bernhard R Winkelmann; Peter J Grant; Hans L Hillege; Francois Cambien; David J Stott; Gordon D Lowe; Timothy D Spector; James B Meigs; Winfried Marz; Per Eriksson; Lewis C Becker; Pierre-Emmanuel Morange; Nicole Soranzo; Scott M Williams; Caroline Hayward; Pim van der Harst; Anders Hamsten; Charles J Lowenstein; David P Strachan; Christopher J O'Donnell
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-02-27       Impact factor: 8.311

10.  Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis.

Authors:  N B Adams; P L Lutsey; A R Folsom; D H Herrington; C T Sibley; N A Zakai; S Ades; G L Burke; M Cushman
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.